The United States insulin market is collectively dominated by the global pharmaceutical trio known as the "Big Three"—Novo Nordisk, Eli Lilly and Company, and Sanofi. These three multinational corporations manufacture and distribute the vast majority of traditional human insulins, rapid-acting analog products, and long-term basal formulations utilized by American patients through various commercial, retail, and public healthcare channels.